Novel regulatory mechanisms controlling hepatic apoB-Lp lipid loading and secretion

控制肝脏apoB-Lp脂质负荷和分泌的新调控机制

基本信息

  • 批准号:
    10628991
  • 负责人:
  • 金额:
    $ 47.3万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-05-01 至 2028-04-30
  • 项目状态:
    未结题

项目摘要

The global hypothesis underlying this PPG application is that crosstalk between adipose, liver, and intravascular lipolysis regulates the biogenesis of atherogenic apoB-containing lipoproteins, most notably VLDLs. Project 2 (P2) focuses on mechanisms that control the generation of apoB/VLDL in liver cells. Prior work from the PI and Co-I, which has resulted in 14 publications, established that a major mechanism controlling circulating apoB/VLDL is the regulated degradation of apoB in the endoplasmic reticulum (ER). This metabolically orchestrated event requires the ER-associated degradation (ERAD) pathway, which was named and first elucidated by the Co-I. Under lipid-poor conditions, the ERAD of apoB begins with its selection by molecular chaperones, which is followed by apoB ubiquitinylation and delivery to the cytoplasmic proteasome. In contrast, when neutral lipids (primarily triacylglycerols) are in excess, apoB is co-translationally lipidated by MTP, and the nascent apoB/VLDL particles are expanded by lipids sourced from ER resident lipid droplets (LDs), and the re- modelled apoB/VLDL particle is packaged into COPII vesicles for delivery to the Golgi and then into circulation. In contrast, the events that regulate the number and composition of lipids assembled with apoB—as well as the packaging of engorged, lipid-rich apoB/VLDL particles into COPII vesicles—are poorly characterized. To these ends, results generated by the PI and his colleagues indicate that two factors, ER-resident proteins KLHL12 and FIT2, play a significant role in controlling lipid assembly onto apoB and the encapsulation of apoB/VLDL into COPII vesicles in vitro and in vivo. These recently acquired data support several new hypotheses: First, that KLHL12 resides at apoB exit sites on the ER that include COPII components, and second that the inefficient integration of apoB into COPII vesicles selects the protein for the recently characterized ER-phagy pathway, which was also elucidated by the Co-I. A characterization of a new liver-specific KLHL12 knockout mouse will be used to define the role of KLHL12 in non-alcoholic fatty liver disease and steatohepatitis. In turn, other recently acquired preliminary data indicate that FIT2 deficiency increases ER membrane lipid content along with the generation of lipid-depleted apoB/VLDLs. Based on the function of FIT2 in forming cytosolic LDs, these data underscore another novel hypothesis, that FIT2 delivers LDs into the ER, where they are then integrated into pre-apoB/VLDL particles in either an MTP-dependent or independent manner. A new liver-specific FIT2 knockout mouse will concomitantly allow for a study of the links between FIT2 and fatty liver disease and steatohepatitis, and also atherosclerosis (because of FIT2 regulation of apoB/VLDL lipid content and composition). Broadly, the Specific Aims of this application are: (1) To define the mechanisms underlying KLHL12-dependent regulation of lipid-rich apoB/VLDL encapsulation into hepatic ER-derived, Golgi-directed transport vesicles, and (2) To define the impact of FIT2 on lipid loading of apoB/VLDL particles and their atherogenicity, both of which require critical collaborations with P1, P3, and Core facilities.
该PPG应用的总体假设是脂肪、肝脏和血管内 脂解调节致动脉粥样硬化的含apoB的脂蛋白,最显著的是VLDL的生物发生。计划2 (P2)主要关注肝细胞中apoB/VLDL生成的控制机制。PI的既往工作, 第一委员会已出版了14份出版物,确定了一个主要的机制, apoB/VLDL是apoB在内质网(ER)中的调节性降解。这种新陈代谢 协调的事件需要ER相关降解(ERAD)途径,该途径被命名为 由Co-I解释。在低脂条件下,apoB的ERAD开始于其被分子选择, 分子伴侣,随后是apoB泛素化并递送至细胞质蛋白酶体。与此相反, 当中性脂质(主要是三酰甘油)过量时,载脂蛋白B被MTP共同脂化, 新生apoB/VLDL颗粒被来自ER驻留脂滴(LD)的脂质扩增, 模型化的apoB/VLDL颗粒被包装到COPII囊泡中,用于递送到高尔基体,然后进入循环。 相反,调节与apoB组装的脂质的数量和组成的事件以及 将充胀的、富含脂质的apoB/VLDL颗粒包装到COPII囊泡中的特性很差。对这些 PI和他的同事产生的结果表明,两个因素,ER驻留蛋白KLHL 12和 FIT 2在控制脂质组装到apoB上和apoB/VLDL包封到apoB/VLDL中中起重要作用。 COPII囊泡在体外和体内。这些最近获得的数据支持了几个新的假设:首先, KLHL 12位于ER上的apoB出口位点,包括COPII组分,其次,低效的 apoB整合到COPII囊泡中为最近表征的ER-吞噬途径选择蛋白质, 这也是由Co-I阐明的。一种新的肝脏特异性KLHL 12基因敲除小鼠的特征将 用于确定KLHL 12在非酒精性脂肪性肝病和脂肪性肝炎中的作用。另一方面,最近 获得的初步数据表明,FIT 2缺乏增加ER膜脂质含量沿着, 脂质耗尽的apoB/VLDL的产生。基于FIT 2在形成细胞溶质LD中的功能,这些数据 强调了另一个新的假设,即FIT 2将LD递送到ER中,然后将其整合到ER中。 前apoB/VLDL颗粒以MTP依赖性或非依赖性方式。一种新的肝脏特异性FIT 2基因敲除 小鼠将同时允许研究FIT 2与脂肪肝疾病和脂肪性肝炎之间的联系, 以及动脉粥样硬化(因为FIT 2调节apoB/VLDL脂质含量和组成)。广义上讲是 本申请的具体目的是:(1)确定KLHL 12依赖性调节的潜在机制, 富含脂质的apoB/VLDL包封到肝ER衍生的高尔基体定向转运囊泡中,和(2)为了定义 FIT 2对载脂蛋白B/极低密度脂蛋白颗粒的脂质负荷及其致动脉粥样硬化性的影响,这两者都需要关键的 与P1、P3和核心设施合作。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Edward A Fisher其他文献

Technology Insight: targeting of biological molecules for evaluation of high-risk atherosclerotic plaques with magnetic resonance imaging
技术洞察:利用磁共振成像靶向生物分子以评估高危动脉粥样硬化斑块
  • DOI:
    10.1038/ncpcardio0013
  • 发表时间:
    2004-11-01
  • 期刊:
  • 影响因子:
    44.200
  • 作者:
    Michael J Lipinski;Valentin Fuster;Edward A Fisher;Zahi A Fayad
  • 通讯作者:
    Zahi A Fayad
Summing up
加起来
  • DOI:
    10.1007/bf00871232
  • 发表时间:
    1947
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Edward A Fisher
  • 通讯作者:
    Edward A Fisher
Rapid regression of atherosclerosis: insights from the clinical and experimental literature
动脉粥样硬化的快速消退:来自临床和实验文献的见解
  • DOI:
    10.1038/ncpcardio1086
  • 发表时间:
    2008-02-01
  • 期刊:
  • 影响因子:
    44.200
  • 作者:
    Kevin Jon Williams;Jonathan E Feig;Edward A Fisher
  • 通讯作者:
    Edward A Fisher

Edward A Fisher的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Edward A Fisher', 18)}}的其他基金

Atherosclerosis core
动脉粥样硬化核心
  • 批准号:
    10628989
  • 财政年份:
    2023
  • 资助金额:
    $ 47.3万
  • 项目类别:
Administrative, Biostatistics, Data Management, and Bioinformatics Core
行政、生物统计学、数据管理和生物信息学核心
  • 批准号:
    10424901
  • 财政年份:
    2017
  • 资助金额:
    $ 47.3万
  • 项目类别:
Administrative, Biostatistics, Data Management, and Bioinformatics Core
行政、生物统计学、数据管理和生物信息学核心
  • 批准号:
    10616527
  • 财政年份:
    2017
  • 资助金额:
    $ 47.3万
  • 项目类别:
Macrophage Dysfunction in Obesity, Diabetes and Atherosclerosis
肥胖、糖尿病和动脉粥样硬化中的巨噬细胞功能障碍
  • 批准号:
    9209582
  • 财政年份:
    2017
  • 资助金额:
    $ 47.3万
  • 项目类别:
Resolving Macrophage Inflammation in Atherosclerotic Plaques and Other Sites in Insulin Resistance
解决动脉粥样硬化斑块和胰岛素抵抗其他部位的巨噬细胞炎症
  • 批准号:
    10424904
  • 财政年份:
    2017
  • 资助金额:
    $ 47.3万
  • 项目类别:
Macrophage Dysfunction in Atherosclerosis and Cardiometabolic Diseases
动脉粥样硬化和心脏代谢疾病中的巨噬细胞功能障碍
  • 批准号:
    10616525
  • 财政年份:
    2017
  • 资助金额:
    $ 47.3万
  • 项目类别:
Macrophage Dysfunction in Atherosclerosis and Cardiometabolic Diseases
动脉粥样硬化和心脏代谢疾病中的巨噬细胞功能障碍
  • 批准号:
    10424900
  • 财政年份:
    2017
  • 资助金额:
    $ 47.3万
  • 项目类别:
Resolving Macrophage Inflammation in Atherosclerotic Plaques and Other Sites in Insulin Resistance
解决动脉粥样硬化斑块和胰岛素抵抗其他部位的巨噬细胞炎症
  • 批准号:
    10616536
  • 财政年份:
    2017
  • 资助金额:
    $ 47.3万
  • 项目类别:
Macrophage Dysfunction in Obesity, Diabetes and Atherosclerosis
肥胖、糖尿病和动脉粥样硬化中的巨噬细胞功能障碍
  • 批准号:
    9925242
  • 财政年份:
    2017
  • 资助金额:
    $ 47.3万
  • 项目类别:
Beta-catenin signaling in endothelial cells during cerebral malaria
脑型疟疾期间内皮细胞中的β-连环蛋白信号传导
  • 批准号:
    9144854
  • 财政年份:
    2015
  • 资助金额:
    $ 47.3万
  • 项目类别:

相似海外基金

Deciphering the role of adipose tissue in common metabolic disease via adipose tissue proteomics
通过脂肪组织蛋白质组学解读脂肪组织在常见代谢疾病中的作用
  • 批准号:
    MR/Y013891/1
  • 财政年份:
    2024
  • 资助金额:
    $ 47.3万
  • 项目类别:
    Research Grant
ESTABLISHING THE ROLE OF ADIPOSE TISSUE INFLAMMATION IN THE REGULATION OF MUSCLE MASS IN OLDER PEOPLE
确定脂肪组织炎症在老年人肌肉质量调节中的作用
  • 批准号:
    BB/Y006542/1
  • 财政年份:
    2024
  • 资助金额:
    $ 47.3万
  • 项目类别:
    Research Grant
Canadian Alliance of Healthy Hearts and Minds: Dissecting the Pathways Linking Ectopic Adipose Tissue to Cognitive Dysfunction
加拿大健康心灵联盟:剖析异位脂肪组织与认知功能障碍之间的联系途径
  • 批准号:
    479570
  • 财政年份:
    2023
  • 资助金额:
    $ 47.3万
  • 项目类别:
    Operating Grants
Determinants of Longitudinal Progression of Adipose Tissue Inflammation in Individuals at High-Risk for Type 2 Diabetes: Novel Insights from Metabolomic Profiling
2 型糖尿病高危个体脂肪组织炎症纵向进展的决定因素:代谢组学分析的新见解
  • 批准号:
    488898
  • 财政年份:
    2023
  • 资助金额:
    $ 47.3万
  • 项目类别:
    Operating Grants
Activation of human brown adipose tissue using food ingredients that enhance the bioavailability of nitric oxide
使用增强一氧化氮生物利用度的食品成分激活人体棕色脂肪组织
  • 批准号:
    23H03323
  • 财政年份:
    2023
  • 资助金额:
    $ 47.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Development of new lung regeneration therapies by elucidating the lung regeneration mechanism of adipose tissue-derived stem cells
通过阐明脂肪组织干细胞的肺再生机制开发新的肺再生疗法
  • 批准号:
    23K08293
  • 财政年份:
    2023
  • 资助金额:
    $ 47.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A study on the role of brown adipose tissue in the development and maintenance of skeletal muscles
棕色脂肪组织在骨骼肌发育和维持中作用的研究
  • 批准号:
    23K19922
  • 财政年份:
    2023
  • 资助金额:
    $ 47.3万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Adipose Tissue T Cell Polarization and Metabolic Health in Persons Living with HIV
HIV 感染者的脂肪组织 T 细胞极化和代谢健康
  • 批准号:
    10619176
  • 财政年份:
    2023
  • 资助金额:
    $ 47.3万
  • 项目类别:
Estrogen Signaling in the Ventromedial Hypothalamus Modulates Adipose Tissue Metabolic Adaptation
下丘脑腹内侧区的雌激素信号调节脂肪组织代谢适应
  • 批准号:
    10604611
  • 财政年份:
    2023
  • 资助金额:
    $ 47.3万
  • 项目类别:
Obesity and Childhood Asthma: The Role of Adipose Tissue
肥胖和儿童哮喘:脂肪组织的作用
  • 批准号:
    10813753
  • 财政年份:
    2023
  • 资助金额:
    $ 47.3万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了